Skip to search formSkip to main contentSkip to account menu

ProMACE-CytaBOM Regimen

Known as: Prednisone-Methotrexate-Adriamycin-Cytoxan-Etoposide-Cytarabine-Bleomycin-Oncovin-Methotrexate Regimen 
A non-cross resistant regimen consisting of prednisone, methotrexate, doxorubicin, cyclophosphamide and etoposide (ProMACE) alternating with… 
National Institutes of Health

Related topics

Related topics

12 relations
BleomycinCyclophosphamideCytarabineDoxorubicin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
[Clinical randomized comparative trial of ProMACE-CytaBOM regimen and CHOP regimen in treating non-Hodgkin's lymphoma].
BACKGROUND & OBJECTIVE CHOP regimen is the routine modality for moderately or highly malignant non-Hodgkin's lymphoma (NHL… 
1998
1998
[Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
INTRODUCTION The Working Formulation Classification (for clinical use) divides non-Hodgkin's lymphoma (NHL), according to the… 
1996
1996
Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.
PURPOSE The aim of this study was to determine the maximum-tolerated dose (MTD) of cyclophosphamide, doxorubicin, etoposide… 
1994
1994
LINFOMI NON HODGKIN AGGRESIVI : POLICHEMIOTERAPIA PROMICE-CYTABOM
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)